The company's core mission is to safeguard patient outcomes through the maintenance of vascular integrity, utilizing a proprietary platform designed to neutralize oxidative damage—a critical driver of vein graft ischemic reperfusion injury. In March 2025, Marizyme entered a non-binding Memorandum of Understanding with Qualigen Therapeutics to be acquired, following a co-marketing agreement established in 2024.
Cyborg Score Rationale
Marizyme is an early-revenue, pre-commercial stage biotech company with minimal market traction. The pending acquisition by Qualigen (as of March 2025) reflects limited standalone viability, and with trailing twelve-month revenue of only $183K and a market cap under $40K, the company faces severe capitalization and operational challenges.
Top Insights
(March 2025) Qualigen Therapeutics entered non-binding MOU to acquire Marizyme with deal expected to provide rapid revenue growth starting in 2025
(March 2026) FDA clearance received for flagship product DuraGraft, addressing saphenous vein graft failure where approximately 50% fail within 5–10 years
Multi-asset pipeline includes DuraGraft (CABG), Krillase (enzyme-based), MATLOC 1 (chronic kidney disease screening), and MAR-FG-001 (fat grafting)
Severely capital-constrained micro-cap with 11 employees, $183K trailing revenue, and $39.5K market capitalization as of April 2025
Named Competitors
Cue Biopharma — Immunotherapy and biotech development
INmune Bio — Immunotherapeutics development
Recent Developments
(March 2025) Non-binding MOU signed with Qualigen Therapeutics (NASDAQ: QLGN) for acquisition
(March 2026) FDA clearance announced for DuraGraft vascular conduit solution
(2024) Co-marketing agreement established with Qualigen Therapeutics
Open the full interactive Marizyme Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.